GOING CONCERN AND LIQUIDITY	3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN AND LIQUIDITY	NOTE 2 — GOING CONCERN AND LIQUIDITY Our financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. The Company has incurred total losses since its inception of $134.6 million. The Company’s operating losses were approximately $828,000 and $2.0 million for the three months ended March 31, 2026, and 2025, respectively. On March 31, 2026, Milestone Scientific had cash and cash equivalents of approximately $1.2 million and working capital of approximately $2.5 million. For the three months ended March 31, 2026 and 2025, we had cash flows provided by (used in) operating activities of approximately $0.1 million and $(1.0) million, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. On April 20, 2026, the Company completed a private placement of 7,962,963 units at a purchase price of $0.27 per unit, generating gross proceeds of approximately $2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s outstanding convertible notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash (the “Private Placement”). Each unit consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $0.3375 per share, exercisable for a period of three years. If fully exercised, the warrants would provide up to approximately $2.69 million in additional gross proceeds. The Company intends to use the net proceeds from the private placement for general working capital purposes and the payment of outstanding accounts payable and accrued liabilities. The Company’s recurring losses from operations, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The completion of the private placement in April 2026 has improved the Company’s liquidity position; however, the Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient revenue, manage operating expenses, and, if necessary, obtain additional financing

GOING CONCERN AND LIQUIDITY

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NOTE 2 — GOING CONCERN AND LIQUIDITY

Our financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements.

The Company has incurred total losses since its inception of $134.6 million. The Company’s operating losses were approximately $828,000 and $2.0 million for the three months ended March 31, 2026, and 2025, respectively. On March 31, 2026, Milestone Scientific had cash and cash equivalents of approximately $1.2 million and working capital of approximately $2.5 million. For the three months ended March 31, 2026 and 2025, we had cash flows provided by (used in) operating activities of approximately $0.1 million and $(1.0) million, respectively. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

On April 20, 2026, the Company completed a private placement of 7,962,963 units at a purchase price of $0.27 per unit, generating gross proceeds of approximately $2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s outstanding convertible notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash (the “Private Placement”).

Each unit consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $0.3375 per share, exercisable for a period of three years. If fully exercised, the warrants would provide up to approximately $2.69 million in additional gross proceeds.

The Company intends to use the net proceeds from the private placement for general working capital purposes and the payment of outstanding accounts payable and accrued liabilities.

The Company’s recurring losses from operations, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The completion of the private placement in April 2026 has improved the Company’s liquidity position; however, the Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient revenue, manage operating expenses, and, if necessary, obtain additional financing

- Definition

The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.

+ References + Details